Zymeworks Inc. announced on October 21, 2024, that the first patient has been dosed in its first-in-human Phase 1 trial (NCT06523803) for the investigational therapy ZW171. This trial aims to evaluate the safety and tolerability of ZW171 in the treatment of advanced or metastatic ovarian cancer, non-small cell lung cancer (NSCLC), and other mesothelin (MSLN)-expressing cancers.
ZW171 is a bispecific antibody designed to enable T cell-mediated tumor cell killing by simultaneously binding to MSLN on tumor cells and engaging CD3 on T cells. Preclinical studies have shown ZW171 to exhibit greater anti-tumor activity compared to benchmarks in MSLN-expressing tumor models and was well-tolerated in cynomolgus monkeys up to 30 mg/kg.
The initiation of this trial represents a significant step forward in Zymeworks' efforts to bring a potential new treatment to patients with difficult-to-treat cancers. It also highlights the company's goal to advance two therapeutic candidates, ZW171 and ZW191, into clinical studies in 2024, showcasing progress in its wholly-owned pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.